GSK to buy Canada's 35Pharma for $950 million
ReutersFeb 25, 2026 7:27 AM
Feb 25 (Reuters) - GSK GSK.L on Wednesday agreed to pay $950 million in cash for Canadian biopharmaceutical company 35Pharma Inc, which is developing a medicine for pulmonary hypertension.
The deal marks GSK's second major acquisition under new CEO Luke Miels, after it agreed to buy RAPT Therapeutics RAPT.O for $2.2 billion in January.
GSK will acquire 35Pharma's in-development drug to treat pulmonary hypertension, a life-shortening disease marked by high blood pressure in the lungs, helping the company expand its respiratory portfolio.
The British drugmaker earlier this week agreed to a $1 billion deal to acquire global rights to develop Frontier Biotechnologies' 688221.SS two small interfering RNA therapies targeting kidney diseases.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Nvidia Q4 Earnings: Market Fears Competition, but NVDA Moat is Beyond CUDA
All eyes are on Nvidia this week, as the company reports its 2026Q4 earnings.TradingKey
7 hours ago
Nvidia Q4 Earnings Preview: AI-Driven Growth Versus Market Expectations
TradingKey - NVIDIA (NVDA) is set to release its fourth quarter fiscal year 2026 earnings report after the market close on February 25, ET. As the world undergoes a period of rapid AI technological advancement, market debates over a capital expenditure bubble have intensified. In this context, NVIDIA’s results serve not only as a test of its business performance but also as a core bellwether for the sustainability of the global AI boom.TradingKey
22 hours ago
Tesla Stock Outlook: Why 2026 Could Be the Year of the Tesla Robotaxi
TradingKey - The concept of autonomous mobility for Tesla(TSLA) has gone from a projection of the far away future to a vital part of its overall long-term growth strategy.TradingKey
23 hours ago
